Loading
A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting.
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis is a phase 3 interventional study registered as NCT05862272 by Sumitomo Pharma Switzerland GmbH, with 1000 participants planned, started 2023-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Relugolix Combination Tablet.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sumitomo Pharma (Myovant) and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.
Shares Relugolix and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.
Shares Sumitomo Pharma (Myovant) and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/